Journal article
The Addition of Fish Oil to Cognitive Behavioral Case Management for Youth Depression: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial
GP Amminger, S Rice, CG Davey, AL Quinn, DF Hermens, N Zmicerevska, A Nichles, I Hickie, L Incerti, A Weller, S Joseph, Z Hilton, C Pugh, M Rayner, N Reid, A Ratheesh, AR Yung, HP Yuen, A Mackinnon, S Hetrick Show all
Biological Psychiatry | ELSEVIER SCIENCE INC | Published : 2024
Abstract
Background: Clinical trials suggest that long-chain omega-3 polyunsaturated fatty acids (n-3 PUFAs) (fish oil) may reduce depressive symptoms in adults with major depressive disorder. Therefore, n-3 PUFAs may be a potential treatment for depression in youth. Methods: Participants were 15- to-25 year-old individuals with major depressive disorder who sought care in one of three government-funded mental health services for young people in metropolitan Melbourne, Perth, or Sydney, Australia. Participants were randomly assigned in a double-blind, parallel-arm design to receive either fish oil (840 mg of eicosapentaenoic acid and 560 mg of docosahexaenoic acid) or placebo capsules as adjunct to c..
View full abstractRelated Projects (4)
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This work was supported by the National Health and Medical Research Council (NHMRC) (Grant No. 1042666 [to GPA] ) , Beyond Blue National Priority Driven Research Program (Grant No. 00096 [to GPA] ) , an NHMRC Senior Research Fellowship (Grant No. 1080963 [to GPA] ) , an NHMRC Career Development Fellowship (No. 1061757/1141738 [to CGD] ) , an NHMRC Centre of Research Excellence Grant (Grant No. 1061043 [to DFH] ) , an NHMRC Senior Principal Research Fellowship (Grant No. 1156072 [to MB] ) , an NHMRC Career Development Fellowship (Grant No. 1158881 [to SR] ) , a Dame Kate Campbell Fellowship from the University of Melbourne, an NHMRC Senior Research Fellowship (Grant No. 566593 [to ARY] ) , an NHMRC Senior Principal Research Fellowship (Grant Nos. APP1059660 and APP1156072 [to MB] ) , an NHMRC Senior Principal Research Fellowship (Grant No. 1060996 [to PDM] ) , and an NHMRC Emerging Leadership Fellowship (Grant No. 2010063 [to AL] ) . PDM reports receiving unrestricted research funding from AstraZeneca, Eli Lilly and Company, Janssen-Cilag, Pfizer, and Novartis and honoraria for educational activities with AstraZeneca, Eli Lilly and Company, Janssen- Cilag, Pfizer, Bristol-Myers Squibb, Roche Holding AG, and the Lundbeck Institute. MB has received research support from the Simons Autism Foundation; the Stanley Medical Research Foundation; Beyond Blue; Rotary Health, Meat and Livestock Board; AstraZeneca; Woolworths; Avant and the Harry Windsor Foundation, and book royalties from Oxford University Press, Cambridge University Press, Springer Nature, and Allen and Unwin. He has been a speaker for AstraZeneca, Lundbeck, Merck, and Servier and has served as a consultant to Allergan, AstraZeneca, Bioadvantex, Bionomics, Collaborative Medicinal Development, Grunbiotics, Janssen-Cilag, Liva- Nova, Lundbeck, Merck, Mylan, Otsuka, and Servier. IH previously led community -based and pharmaceutical industry-supported projects (Wyeth, Eli Lilly, Servier, Pfizer, AstraZeneca) focused on the identification and better management of anxiety and depression. He was a member of the Medical Advisory Panel for Medibank Private until October 2017, a board member of the Psychosis Australia Trust, and a member of the Veterans Mental Health Clinical Reference group. He is the chief scientific adviser to and a 5% equity shareholder in InnoWell Pty Ltd. All other authors report no biomedical financial interests or potential conflicts of interest. Australia New Zealand Clinical Trials Registry: Youth Depression Alleviation: A randomized controlled trial of Omega -3 Fatty Acids (Fish Oil) for Major Depressive Disorder in Young People (YoDA-F) ; https:// www.anzctr. org.au/; ACTRN12613001352796.